Derek Wallace
Overview
Explore the profile of Derek Wallace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kandeil W, Nascimento E, Tricou V, Sharma M, Wallace D
EBioMedicine
. 2024 Sep;
108:105370.
PMID: 39342806
No abstract available.
2.
Fernando L, Kastner R, Wickramasinghe P, Fernando A, Gunasekera D, Nguyen V, et al.
PLoS Negl Trop Dis
. 2024 Aug;
18(8):e0012376.
PMID: 39173075
Background: Outbreaks of dengue can overburden hospital systems, drastically reducing capacity for other care. The 2017 dengue serotype 2 (DENV-2) outbreak in Sri Lanka coincided with vaccination in an ongoing...
3.
Sirivichayakul C, Biswal S, Saez-Llorens X, Lopez-Medina E, Borja-Tabora C, Bravo L, et al.
J Infect Dis
. 2024 Apr;
230(6):e1214-e1225.
PMID: 38682569
Background: We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. Methods: Children 4-16 years of age...
4.
Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al.
Lancet Glob Health
. 2024 Jan;
12(2):e257-e270.
PMID: 38245116
Background: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in...
5.
Tricou V, Winkle P, Tharenos L, Rauscher M, Escudero I, Hoffman E, et al.
Vaccine
. 2023 Oct;
41(47):6999-7006.
PMID: 37884415
Background: We conducted a trial to demonstrate immunogenic equivalence of three consecutive manufacturing lots of Takeda's tetravalent dengue vaccine candidate, TAK-003, and further assessed its safety and reactogenicity. Methods: Healthy...
6.
Tricou V, Essink B, Ervin J, Turner M, Escudero I, Rauscher M, et al.
PLoS Negl Trop Dis
. 2023 Mar;
17(3):e0011124.
PMID: 36888687
Background: Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently...
7.
Saez-Llorens X, Biswal S, Borja-Tabora C, Fernando L, Liu M, Wallace D, et al.
Am J Trop Med Hyg
. 2023 Mar;
108(4):722-726.
PMID: 36878213
In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue...
8.
Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, et al.
Vaccine
. 2023 Jan;
41(7):1398-1407.
PMID: 36681529
Background: Vaccination against hepatitis A virus (HAV) is largely recommended for travelers worldwide. Concurrent dengue and HAV vaccination may be desired in parallel for travelers to countries where both diseases...
9.
Tricou V, Gottardo R, Egan M, Clement F, Leroux-Roels G, Saez-Llorens X, et al.
Vaccine
. 2022 Jan;
40(8):1143-1151.
PMID: 35078666
Background: As robust dengue-specific CD4+ and CD8+ T cell responses are essential for protective immunity, we assessed cell-mediated immune (CMI) responses to a DENV-2-based dengue tetravalent vaccine candidate (TAK-003) in...
10.
Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C, et al.
Clin Infect Dis
. 2021 Oct;
75(1):107-117.
PMID: 34606595
Background: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in...